During a Case-Based Roundtable® event, Daniel J. George, MD, discusses how often community oncology participants see patients ...

Experts examine both overall survival outcomes and independent review committee–assessed progression-free survival data from ...

Potential practice-changing therapies in gynecologic cancer include the emergence of carboplatin, paclitaxel, and PD-1 ...

Josep Maria Ribera, MD, PhD, discusses the current standard treatment protocols for Philadelphia chromosome-positive acute lymphoblastic leukemia and the rationale behind them.

Sacituzumab govitecan, currently indicated in triple-negative breast cancer (TNBC), is undergoing evaluation in NSCLC. In ...

Alfa, MD, discusses neratinib and its use as a monotherapy and in combination with immune checkpoint inhibitors and/or mTOR inhibitors in the SUMMIT trial.

A new drug application seeking the accelerated approval of dordaviprone forrecurrent for H3K27M-mutant diffuse glioma treatment was submitted to the FDA.

On December 20, 2024, the FDA granted accelerated approval to the combination of encorafenib (Braftovi), cetuximab (Erbitux), and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) in metastatic ...

Panelists discuss how to approach treatment decisions for a 74-year-old patient with transplant-ineligible newly diagnosed multiple myeloma patient, considering factors such as age, comorbidities, and ...

The FDA indicated paxalisib's overall survival data could support standard approval in glioblastoma, as supported by ...

A biologics license application for TLX250-CDx has been submitted to the FDA, as supported by the phase 3 ZIRCON trial ...

The past 12 months have seen the FDA approvals of enfortumab vedotin plus pembrolizumab for patients with locally advanced or ...